Screening fOR Throat Cancer (SORT)
SORT (Screening fOR Throat Cancer)
This study will screen people for biomarkers of Human Papillomavirus (HPV) to form a cohort of people who may be at increased risk of HPV-oropharyngeal cancer (HPV-OPC). The investigators will follow these individuals prospectively to evaluate risk for OPC.
Studieöversikt
Status
Status
Betingelser
Betingelser
Detaljerad beskrivning
This study will assess HPV16 biomarkers, including serum HPV16 E6 antibodies, plasma and oral HPV16 DNA, and ultrasound, to understand the feasibility and utility of HPV16 biomarker screening to identify those at increased risk of HPV-OPC. This study will screen approximately 2500 people. The focus of the study is to determine whether sequential testing for oral and plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies among people with and without HIV. The study includes community screening, as well as biobank screening with longitudinal follow-up of those who screen positive.
Study Design Overview: This study has an initial screen that includes two populations: screening of biobank samples "biobank group" and screening of healthy members of the community "community group" which can be done via an in-person visit or via remote sample collection. The subset of participants with HPV16 biomarkers detected will be asked to join the longitudinal follow-up. During follow-up, participants will have more samples collected and have a neck ultrasound to look for any precancerous lesions.
The study is led by Dr. Amber D'Souza and Dr. Carole Fakhry (Johns Hopkins). Participants are being enrolled from the MWCCS cohort, from Baltimore, MD, and across the US. If interested, complete the study eligibility form at [link coming] or email hpv@jhu.edu with questions.
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: Amber D'Souza, PhD
- Telefonnummer: 410-502-2583
- E-post: gdsouza2@jhu.edu
Studieorter
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21205
- Johns Hopkins Hospital
-
Kontakt:
- Amber D'Souza, PhD
- Telefonnummer: 410-502-2583
- E-post: gdsouza2@jhu.edu
-
Huvudutredare:
- Amber D'Souza, PhD
-
Huvudutredare:
- Carole Fakhry, MD, MPH
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
The study population will be drawn from multiple sources, including healthy men from the broader U.S. population interested in the study via online self-referral, website outreach, or study outreach, as well as participants from the MACS WIHS Combined Cohort Study (MWCCS).
Beskrivning
Inclusion Criteria:
- Part I: Participants in Screening
To be eligible to participate in Part I of this study, an individual must meet the following criteria:
Community and Internet Screen eligibility:
- Male, 40-69 years old
- Willing to self-collect or come in person to collect screening biospecimens
- Willing to be contacted to arrange follow-up visits, if determined to be eligible for follow-up
- Ability to understand and the willingness to sign a written informed consent document
Biorepository Screen eligibility:
-
Male, 40-69 years old
-
Active participant within MWCCS
-
Willing to be contacted to arrange follow-up visits, if determined to be eligible for follow-up
-
Ability to understand and the willingness to sign a written informed consent document
- Part II: Participants in Follow-Up
To be eligible to participate in Part II of this study, an individual must meet all of the following criteria:
- HPV16 biomarker detected in Part I screen
- Willingness to complete annual follow-up visits
Exclusion Criteria:
- Part I: Participants in Screening
An individual who meets any of the following criteria will be excluded from participation in this study:
-
Presence of medical or psychiatric condition affecting ability to give voluntary, informed consent.
-
Participants who do not speak English cannot enroll because the consent and study survey are only available in English. However, if there is a hearing, literacy, or minor fluency issue and the participant requests assistance from a family member or the study coordinator, this individual may still enroll and receive this assistance to ensure the participant fully hears and understands everything being asked.
-
History of head and neck cancer
- Part II: Participants in Follow-Up
An individual who meets any of the following criteria will be excluded from participation in this part of the study:
• Unable to complete annual follow-up visits
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Antal grupper/kohorter
Kohorter och interventioner
Grupp / KohortGrupp / Kohort |
|---|
|
Prospective Observational Cohort
Prospective cohort of adult male participants from two groups: community group (see eligibility form) an biobank group (enrolled from MWCCS cohort). Both groups will undergo initial screening, with eligible participants continuing onto follow-up testing, which may include blood collection, oral rinse collection, anal Pap smear, ultrasound imaging, and surveys. |
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
HPV16 E6 antibodies present or absent in serum sample
Tidsram: Baseline to end of three-year follow-up
|
To determine whether sequential testing for oral or plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies. |
Baseline to end of three-year follow-up
|
|
Oral HPV16 DNA present or absent
Tidsram: Baseline to end of three-year follow-up
|
To determine whether sequential testing for oral HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies. |
Baseline to end of three-year follow-up
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Feasibility of community screening
Tidsram: Baseline to end of three-year follow-up
|
To assess whether primary screening in a community setting of healthy individuals can lead to at least 80% of those with HPV16 E6 antibodies identified agreeing to complete follow-up biomarker collection and ultrasound for secondary screening. |
Baseline to end of three-year follow-up
|
Samarbetspartners och utredare
Sponsor
Sponsor
Samarbetspartners
Samarbetspartners
Publikationer och användbara länkar
Allmänna publikationer
- D'Souza G, Tewari SR, Troy T, Waterboer T, Struijk L, Castillo R, Wright H, Shen M, Miles B, Johansson M, Robbins HA, Fakhry C. Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study. Cancer. 2023 Aug 1;129(15):2373-2384. doi: 10.1002/cncr.34783. Epub 2023 Apr 9.
- Scott-Wittenborn N, D'Souza G, Tewari S, Rooper L, Troy T, Drake V, Bigelow EO, Windon MJ, Ryan WR, Ha PK, Kiess AP, Miles B, Westra WH, Mydlarz WK, Eisele DW, Fakhry C. Prevalence of human papillomavirus in head and neck cancers at tertiary care centers in the United States over time. Cancer. 2022 May 1;128(9):1767-1774. doi: 10.1002/cncr.34124. Epub 2022 Feb 8.
- Scott-Wittenborn N, D'Souza G, Aygun N, Tewari SR, Azadi J, Vosler P, Gooi Z, Mehta V, Mydlarz W, Nance M, Mlot S, Patel MR, Tan M, Miles BA, Troy T, Fakhry C. Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer. Head Neck. 2023 Jan;45(1):95-102. doi: 10.1002/hed.27212. Epub 2022 Oct 6.
- Tewari SR, D'Souza G, Troy T, Wright H, Struijk L, Waterboer T, Fakhry C. Association of Plasma Circulating Tumor HPV DNA With HPV-Related Oropharynx Cancer. JAMA Otolaryngol Head Neck Surg. 2022 May 1;148(5):488-489. doi: 10.1001/jamaoto.2022.0159.
- D'Souza G, Tewari SR, Troy T, Webster-Cyriaque J, Wiley DJ, Lahiri CD, Palella FJ, Gillison ML, Strickler HD, Struijk L, Waterboer T, Ho K, Kwait J, Lazar J, Weber KM, Fakhry C. Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years. Cancer Epidemiol Biomarkers Prev. 2024 Apr 3;33(4):516-524. doi: 10.1158/1055-9965.EPI-23-1272.
- DSouza G, Tewari S, Troy T, Bleyer P, Korley M, Kwait J, Ho K, Gillison M, Wiley D, Lazar J, Weber KM, Strickler H, Lahiri CD, Palella F, Struijk L, Fakhry C. Oral HPV incidence and risk factors for acquisition. Oral Oncol. 2025 Apr;163:107249. doi: 10.1016/j.oraloncology.2025.107249. Epub 2025 Mar 17.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Stomatogena sjukdomar
- Patologiska processer
- Neoplasmer efter plats
- Neoplasmer
- Sjukdomsegenskaper
- Infektioner
- Neoplasmer i huvud och hals
- Otorhinolaryngologiska sjukdomar
- Faryngeala neoplasmer
- Otorhinolaryngologiska neoplasmer
- Faryngeala sjukdomar
- Patologiska tillstånd, tecken och symtom
- Ihållande infektion
- Orofaryngeala neoplasmer
Andra studie-ID-nummer
Andra studie-ID-nummer
- IRB00119537-2
- R56DE036518 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The investigators will utilize a plan for the controlled release, management, and sharing of data. Data will be made available through a study research proposal process.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .